

Andrew J Lloyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6031259/publications.pdf>

Version: 2024-02-01

41
papers

3,784
citations

394421

19
h-index

276875

41
g-index

42
all docs

42
docs citations

42
times ranked

7449
citing authors

#	ARTICLE	IF	CITATIONS
1	Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. <i>Value in Health</i> , 2012, 15, 708-715.	0.3	1,381
2	Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. <i>Value in Health</i> , 2011, 14, 403-413.	0.3	1,342
3	Health state utilities in non-small cell lung cancer: An international study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e195-e203.	1.1	169
4	Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. <i>International Psychogeriatrics</i> , 2006, 18, 151-162.	1.0	104
5	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2016, 19, 704-719.	0.3	101
6	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2019, 22, 267-275.	0.3	98
7	What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life?. <i>Value in Health</i> , 2018, 21, 449-455.	0.3	58
8	Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden. <i>Pharmacoeconomics</i> , 2019, 37, 845-865.	3.3	46
9	Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. <i>Value in Health</i> , 2021, 24, 812-821.	0.3	39
10	The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis. <i>Quality of Life Research</i> , 2017, 26, 1879-1885.	3.1	38
11	Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. <i>British Journal of Ophthalmology</i> , 2019, 103, 1610-1614.	3.9	38
12	Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients. <i>Value in Health</i> , 2015, 18, 1152-1157.	0.3	32
13	A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis. <i>BMC Health Services Research</i> , 2013, 13, 346.	2.2	28
14	Patient preferences for asthma therapy: a discrete choice experiment. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 241-248.	2.3	25
15	Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 310.	2.4	25
16	A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. <i>Journal of Medical Economics</i> , 2017, 20, 863-870.	2.1	24
17	Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1839-1845.	1.3	23
18	How does the EQ-5D-Y Proxy version 1 perform in 3, 4 and 5-year-old children?. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 149.	2.4	23

#	ARTICLE	IF	CITATIONS
19	<p>Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 615-622.	1.9	22
20	Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. Leukemia and Lymphoma, 2015, 56, 1320-1326.	1.3	20
21	Health-related quality of life in Parkinsonâ€™s: impact of â€™ time and stated treatment preferences. Quality of Life Research, 2016, 25, 1505-1515.	3.1	18
22	Patient preferences and willingness to pay for innovations in intermittent self-catheters. Patient Preference and Adherence, 2015, 9, 381.	1.8	17
23	Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder. CNS Spectrums, 2017, 22, 31-40.	1.2	15
24	Special Edition on Utility Measurement, Pharmacoeconomics. Pharmacoeconomics, 2017, 35, 5-6.	3.3	13
25	Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study. Future Oncology, 2021, 17, 4275-4287.	2.4	12
26	Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Preference and Adherence, 2015, 9, 1561.	1.8	11
27	Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued?. Current Medical Research and Opinion, 2020, 36, 609-611.	1.9	8
28	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. European Journal of Health Economics, 2021, 22, 723-733.	2.8	7
29	Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries. Pharmacoeconomics, 2021, 39, 901-912.	3.3	6
30	The QALY at 50: One story many voices. Social Science and Medicine, 2022, 296, 114653.	3.8	6
31	Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment. Current Medical Research and Opinion, 2017, 33, 23-29.	1.9	5
32	How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study. Quality of Life Research, 2021, 30, 2081-2096.	3.1	5
33	Gains in health utility associated with urinary catheter innovations. Medical Devices: Evidence and Research, 2018, Volume 11, 345-351.	0.8	4
34	Estimation of the Quality-of-Life Impact of X-Linked Myotubular Myopathy. Journal of Neuromuscular Diseases, 2021, 8, 1047-1061.	2.6	4
35	Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. Journal of Patient-Reported Outcomes, 2021, 5, 65.	1.9	4
36	Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. Pharmacoeconomics, 2021, , 1.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries. <i>Pharmacoeconomics</i> , 2022, 40, 103-115.	3.3	3
38	Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. <i>Pharmacoeconomics - Open</i> , 2021, , 1.	1.8	2
39	Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. <i>Pharmacoeconomics - Open</i> , 2021, , 1.	1.8	2
40	Estimating health state utilities in hemophagocytic lymphohistiocytosis. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 12.	1.9	1
41	Performance of the Toddler and Infant (TANDI) Health-Related Quality of Life Instrument in 3-4-Year-Old Children. <i>Children</i> , 2021, 8, 920.	1.5	0